Cardiol Therapeutics Inc (NASDAQ:CRDL) shares, rose in value on Thursday, April 16, without any change to the previous day’s close as strong demand from buyers drove the stock to $1.01.
Actively observing the price movement in the last trading, the stock closed the session at $1.01, falling within a range of $0.96 and $1.02. The value of beta (5-year monthly) was 0.67. Referring to stock’s 52-week performance, its high was $3.12, and the low was $0.77. On the whole, CRDL has fluctuated by -14.41% over the past month.
With the market capitalization of Cardiol Therapeutics Inc currently standing at about $83.44 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-01.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRDL’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CRDL currently trading nearly 4.47% and -8.38% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.79, while the 7-day volatility ratio is showing 9.59% which for the 30-day chart, stands at 10.49%. Furthermore, Cardiol Therapeutics Inc (CRDL)’s beta value is 0.93, and its average true range (ATR) is 0.10.
A comparison of Cardiol Therapeutics Inc (CRDL) with its peers suggests the former has fared considerably weaker in the market. CRDL showed an intraday change of 0.00% in last session, and over the past year, it shrunk by -41.28%%.
Data on historical trading for Cardiol Therapeutics Inc (NASDAQ:CRDL) indicates that the trading volumes over the past 10 days have averaged 0.21 and over the past 3 months, they’ve averaged 247.53K. According to company’s latest data on outstanding shares, there are 82.61 million shares outstanding.
Nearly 4.76% of Cardiol Therapeutics Inc’s shares belong to company insiders and institutional investors own 9.26% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.85 million shares as on 2025-03-31, resulting in a short ratio of 7.85. According to the data, the short interest in Cardiol Therapeutics Inc (CRDL) stood at 232.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 1.87 million. The stock has fallen by -21.09% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRDL stock heading into the next quarter.
